Press release

Oncopeptides releases first quarter 2024 sales

April 04, 2024 Regulatory

Stockholm – April 4, 2024 – Oncopeptides AB (STO: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the unaudited net sales for the first quarter of 2024.

Oncopeptides releases this information ahead of the interim report for the first quarter 2024, scheduled for release on May 30, due to the ongoing rights issue process.

“Our first quarter sales are in line with our expectations, and we are tracking according to our plan to become profitable by the end of 2026,” says Sofia Heigis, CEO of Oncopeptides. “The market for multiple myeloma treatments is always hampered by high infection rates during the first few months of the year. Despite this and in contrast to many of our competitors, Pepaxti sales in Q1 2024 remained stable compared to Q4 2023. Looking ahead, increasing sales momentum in Germany, Greece and upcoming launches in Spain and the Middle East and North Africa region makes us confident in accelerated sales during 2024 towards profitability by 2026.”

Financial overview – January-March 2024

  • Based on unaudited figures, Oncopeptides expects Net sales to amount to SEK 5.1 million (SEK 1.1 million).

For more information, please visit